Abstract
Pemigatinib For Previously Treated Central Nervous System Tumors With Activating FGFR Mutations or Translocations: Results From FIGHT-207 (S17.004)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have